Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
University of Toronto
$105,000.00
Dissecting regulatory circuitry governing fungal drug tolerance composed of Hsp90, calcineurin, Cas5 and protein kinase C signaling
EF 2012-13
Résumé
Candida albicans is a major opportunistic fungal pathogen that can cause severe, life-threatening bloodstream and deep organ infections in the growing population of immunocompromised individuals, with associated mortality rates approaching 40%. Although antifungal drugs are routinely used to treat Candida infections, their therapeutic efficacy is limited by the drug tolerance of fungal pathogens. The molecular chaperone heat shock protein 90 (Hsp90) stabilizes diverse client proteins, and is a key modulator of drug tolerance in C. albicans. Recent studies suggest that Hsp90 stimulates responses to drug-induced cell wall stress through its client protein calcineurin and the cell wall integrity pathway mediated by protein kinase Pkc1. The goal of my research is to elucidate the Hsp90-dependent regulatory circuitry that controls tolerance to the echinocandins, which target the fungal cell wall and are the only new class of antifungal to reach the clinic in decades. My initial research suggests that Pkc1 is a client protein of Hsp90, and identifies a novel target downstream of both Pkc1 and calcineurin with a key role in drug tolerance, the transcription factor Cas5. My results suggest that although Pkc1 and calcineurin play a role in regulating CAS5 gene expression, the expression of CAS5 alone is not sufficient to confer tolerance to the echinocandin caspofungin, leading to my current hypothesis that Pkc1 and calcineurin may post-translationally modify Cas5 protein to enable it to function in concert with other transcription factors such as Crz1 and Rlm1. My future research will elucidate the mechanism(s) by which the Hsp90 clients Pkc1 and calcineurin control tolerance to caspofungin in C. albicans via Cas5. My work suggests novel cellular circuitry through which Hsp90 regulates drug tolerance and implicates Cas5, a fungal-specific protein downstream of Pkc1 and calcineurin, as a novel therapeutic target for the treatment of life-threatening fungal diseases.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
283841
Name
Xie Jing Lin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Dissecting regulatory circuitry governing fungal drug tolerance composed of Hsp90, calcineurin, Cas5 and protein kinase C signaling
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Candida Albicans; Cellular Signalling; Fungal Drug Resistance; Molecular Chaperone
Abstract
Candida albicans is a major opportunistic fungal pathogen that can cause severe, life-threatening bloodstream and deep organ infections in the growing population of immunocompromised individuals, with associated mortality rates approaching 40%. Although antifungal drugs are routinely used to treat Candida infections, their therapeutic efficacy is limited by the drug tolerance of fungal pathogens. The molecular chaperone heat shock protein 90 (Hsp90) stabilizes diverse client proteins, and is a key modulator of drug tolerance in C. albicans. Recent studies suggest that Hsp90 stimulates responses to drug-induced cell wall stress through its client protein calcineurin and the cell wall integrity pathway mediated by protein kinase Pkc1. The goal of my research is to elucidate the Hsp90-dependent regulatory circuitry that controls tolerance to the echinocandins, which target the fungal cell wall and are the only new class of antifungal to reach the clinic in decades. My initial research suggests that Pkc1 is a client protein of Hsp90, and identifies a novel target downstream of both Pkc1 and calcineurin with a key role in drug tolerance, the transcription factor Cas5. My results suggest that although Pkc1 and calcineurin play a role in regulating CAS5 gene expression, the expression of CAS5 alone is not sufficient to confer tolerance to the echinocandin caspofungin, leading to my current hypothesis that Pkc1 and calcineurin may post-translationally modify Cas5 protein to enable it to function in concert with other transcription factors such as Crz1 and Rlm1. My future research will elucidate the mechanism(s) by which the Hsp90 clients Pkc1 and calcineurin control tolerance to caspofungin in C. albicans via Cas5. My work suggests novel cellular circuitry through which Hsp90 regulates drug tolerance and implicates Cas5, a fungal-specific protein downstream of Pkc1 and calcineurin, as a novel therapeutic target for the treatment of life-threatening fungal diseases.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Xie, Jing Lin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~